Qilian International Holding Group
General Information | |
Business: | Through our wholly owned indirect subsidiaries and the contractual arrangements described below, we are a pharmaceutical and chemical company based in China that focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives (“TCMD”) product, heparin product, sausage casings, and fertilizers. We independently developed all of our products within our research and development department. Our products are sold in more than 20 provinces in China. (Note: Qilian priced its IPO at $5, the low end of its $5-to-$7 range, on Jan. 11, 2021, on 5 million shares, the same number of shares in the prospectus, to raise $25.0 million.)
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 279 |
Founded: | 2019 |
Contact Information | |
Address | Jiuquan Economic and Technological Development Zone, Jiuquan City, Gansu Province, 735000 People’s Republic of China |
Phone Number | +86-0937-2689523 |
Web Address | |
View Prospectus: | Qilian International Holding Group |
Financial Information | |
Market Cap | $175mil |
Revenues | $46.7 mil (last 12 months) |
Net Income | $3.8 mil (last 12 months) |
IPO Profile | |
Symbol | QLI |
Exchange | NASDAQ |
Shares (millions): | 5.0 |
Price range | $5.00 - $5.00 |
Est. $ Volume | $25.0 mil |
Manager / Joint Managers | Univest Securities |
CO-Managers | Loop Capital Markets/ Alexander Capital |
Expected To Trade: | 1/12/2021 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |